OncLive TV

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.

Mary-Ellen Taplin, MD, discusses efforts to address disparities in access to, and delivery of, prostate cancer care.

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

Jason Efstathiou, MD, DPhil, discusses the role of tri-modality therapy in patients with muscle-invasive bladder cancer.

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.

Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.

Oliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Kelly E. McCann, MD, PhD, discusses her experiences with mentorship and work-life balance as a woman in oncology.

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Neeraj Agarwal, FASCO, MD, discusses quality of life considerations for patients with prostate cancer.

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.